EGF receptor is required for KRAS-induced pancreatic tumorigenesis
about
Genetic determinants and potential therapeutic targets for pancreatic adenocarcinomaEmerging concepts in pancreatic cancer medicine: targeting the tumor stromaPancreatic Cancer from Molecular Pathways to Treatment OpinionMolecular therapeutics in pancreas cancerThe Significance of Ras Activity in Pancreatic Cancer InitiationNeutrophil-Derived Proteases in the Microenvironment of Pancreatic Cancer -Active Players in Tumor ProgressionMolecular Biomarkers of Pancreatic Intraepithelial Neoplasia and Their Implications in Early Diagnosis and Therapeutic Intervention of Pancreatic CancerGenetics and biology of pancreatic ductal adenocarcinomaMolecular targets for the treatment of pancreatic cancer: Clinical and experimental studiesPerspectives in the treatment of pancreatic adenocarcinomaMolecular Targeted Intervention for Pancreatic CancerReserve stem cells: Differentiated cells reprogram to fuel repair, metaplasia, and neoplasia in the adult gastrointestinal tractProtein kinase D enzymes: novel kinase targets in pancreatic cancerMechanistic target of rapamycin (mTOR): a point of convergence in the action of insulin/IGF-1 and G protein-coupled receptor agonists in pancreatic cancer cellsGenetically engineered mouse models of pancreatic adenocarcinomaADAM8 as a drug target in pancreatic cancer.Silencing Mist1 Gene Expression Is Essential for Recovery from Acute PancreatitisRole of bile acids in carcinogenesis of pancreatic cancer: An old topic with new perspective.Utilizing past and present mouse systems to engineer more relevant pancreatic cancer modelsEpidermal growth factor signaling in transformed cellsRegulation of Cellular Identity in CancerInterleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistanceNeuropilin-2 Regulates Endosome Maturation and EGFR Trafficking to Support Cancer Cell Pathobiology.Gene expression profile analysis of pancreatic cancer based on microarray data.Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotiniKRAS-dependent suppression of MYC enhances the sensitivity of cancer cells to cytotoxic agents.Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward.MAPK signaling is required for dedifferentiation of acinar cells and development of pancreatic intraepithelial neoplasia in mice.The quest to overcome resistance to EGFR-targeted therapies in cancer.Inflammation to cancer: The molecular biology in the pancreas (Review).Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) geneCholecystokinin and pancreatic cancer: the chicken or the egg?The secret origins and surprising fates of pancreas tumorsRacial disparity in metabolic regulation of cancer.Cooperativity of oncogenic K-ras and downregulated p16/INK4A in human pancreatic tumorigenesis.Areca nut components affect COX-2, cyclin B1/cdc25C and keratin expression, PGE2 production in keratinocyte is related to reactive oxygen species, CYP1A1, Src, EGFR and Ras signaling.Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts.Oncogenic KRAS signalling in pancreatic cancer.pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104TACE/ADAM17 is essential for oligodendrocyte development and CNS myelination.
P2860
Q21129230-4B57E6B6-0AE5-44C3-A3F9-9AB61C92AB44Q24627664-36E504D2-5A24-4132-BFB0-3354FBB4CC7FQ26743482-B798419B-1192-4324-A9D7-00AEA48FB5E5Q26751709-26ADA536-1937-48B3-B367-40D16033CBBEQ26765230-7CFE67E8-1EE8-4B2D-BC97-E4BB52F0A754Q26765238-F88236E0-3E43-47F9-96E3-A85E3672D2B5Q26765241-B6B02B51-21A0-4BAF-8B8B-9A7EB3456AECQ26765438-80890F55-4E79-4832-A10B-5E09B729A404Q26774636-B0E708B7-B42C-480C-9030-CAAE0B7E2F35Q26797248-F5B8EF96-BE5A-4356-A705-BB99F1EE8AF5Q26798453-7E022099-B57E-4BFC-89B1-1221E06B16BBQ26801731-73BF61CF-52B9-4C9A-8245-50C4F8682870Q26801854-9176BD5B-CE19-4293-A739-6800D5C25B24Q26827387-4C953D7C-401B-4C2B-BDCC-56EE7D15E503Q27002973-42EE3BD3-F2CD-4717-87BC-5DFB9978D54EQ27324447-5C05D144-DB5D-445C-B0D4-30B1969D3FCBQ27334054-61F7F514-A3B2-440E-BF93-1531B64C2899Q27693345-AE407AC7-4C6D-4033-860E-08B64A563F98Q28083091-908AE377-5BAE-4764-9985-671D3FDB0EFDQ28084034-7996B5D6-C191-4285-B626-B8C4058D81BFQ28086849-F850B15E-3D92-415A-A3B1-CFF94649FCABQ28504893-83416E05-48E3-41FE-9F5E-D64ADB1E0495Q30699331-D36BA2CB-1418-45AE-8580-FD5CFE69F1BEQ31066570-A49829A8-6FE9-48EF-8E77-118B5C3D6B91Q33416585-9F4799B2-7487-44CF-9F3F-3A3A522341B4Q33566777-A4929D24-AF95-4ACB-9F2F-C798CD189474Q33624574-7788CF0C-B4A8-4D91-A6A8-B2AC7A73016CQ33680759-AEAE74E1-C93C-4E0E-A2A3-898F4613DD7EQ33725976-49FFEC67-9905-4516-8C2A-23BFD37199F7Q33727657-9A39B9E9-1450-4E47-9FE7-56639D196D26Q33779491-97C0C9FD-17C5-4645-A82E-9379251EE18AQ33816883-22BC77D0-08C6-4FAC-887A-7AE5DB6D8B7EQ33827679-95EA7348-AA4E-4B2C-9B52-5676E538C07CQ33906704-0C1CD754-3E09-4E8F-AFE1-1B4D53332B5DQ33910221-748DA3C8-B4AC-4812-8196-EB3AB876D282Q33933185-11766D90-1519-40FE-BAA7-835FEE0176A8Q34067863-C1FF32ED-B599-4CEB-B3D6-E78CB92B239EQ34113460-EE71C00F-0B91-4A88-9156-23F5C24D8349Q34123654-FA058992-B4B8-4C96-B230-BB5696F6D5E2Q34123782-D85FAF46-C57A-4F76-8EDC-B570237390FA
P2860
EGF receptor is required for KRAS-induced pancreatic tumorigenesis
description
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2012
@ast
im September 2012 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2012/09/11)
@sk
vědecký článek publikovaný v roce 2012
@cs
wetenschappelijk artikel (gepubliceerd op 2012/09/11)
@nl
наукова стаття, опублікована у вересні 2012
@uk
مقالة علمية (نشرت في 11-9-2012)
@ar
name
EGF receptor is required for KRAS-induced pancreatic tumorigenesis
@ast
EGF receptor is required for KRAS-induced pancreatic tumorigenesis
@en
EGF receptor is required for KRAS-induced pancreatic tumorigenesis
@nl
type
label
EGF receptor is required for KRAS-induced pancreatic tumorigenesis
@ast
EGF receptor is required for KRAS-induced pancreatic tumorigenesis
@en
EGF receptor is required for KRAS-induced pancreatic tumorigenesis
@nl
prefLabel
EGF receptor is required for KRAS-induced pancreatic tumorigenesis
@ast
EGF receptor is required for KRAS-induced pancreatic tumorigenesis
@en
EGF receptor is required for KRAS-induced pancreatic tumorigenesis
@nl
P2093
P2860
P50
P3181
P1433
P1476
EGF receptor is required for KRAS-induced pancreatic tumorigenesis
@en
P2093
Alexander Herner
Bence Sipos
Carole L Wilson
Christine M Ardito
Christopher J Halbrook
Eileen S Carpenter
Elaine W Raines
Geou-Yarh Liou
Howard C Crawford
Jason C Hall
P2860
P304
P3181
P356
10.1016/J.CCR.2012.07.024
P50
P577
2012-09-01T00:00:00Z